Allosteric inhibition of factor XIa. Sulfated non-saccharide glycosaminoglycan mimetics as promising anticoagulants

Thrombosis Research

Volumn 136, Issue 2, 2015, Pages 379-387

  Al Horani, Rami A ^a   Gailani, David ^b   Desai, Umesh R ^a  

^a VIRGINIA COMMONWEALTH UNIVERSITY   (United States)

^b VANDERBILT UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACTIVATED PROTEIN C; ANTICOAGULANT AGENT; ANTITHROMBIN; ARGININE; BLOOD CLOTTING FACTOR 11A; BLOOD CLOTTING FACTOR 13A; CHONDROITIN 4 SULFATE; CHONDROITIN 6 SULFATE; DERMATAN SULFATE; ENOXAPARIN; FONDAPARINUX; GLUCOPYRANOSIDE; GLYCOSAMINOGLYCAN POLYSULFATE; HEPARIN COFACTOR II; HEXADIMETHRINE BROMIDE; LYSINE; PLASMA KALLIKREIN; PROTAMINE; SERINE PROTEINASE INHIBITOR; SERUM ALBUMIN; SUCROSOFATE; SULFATED PENTAGALLOYL GLUCOPYRANOSIDE; UNCLASSIFIED DRUG; BIOMIMETIC MATERIAL; GLUCOSIDE; PROTEIN BINDING; SULFATE; SULFATED PENTAGALLOYLGLUCOSIDE;

ALLOSTERISM; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTICOAGULATION; ARTICLE; BINDING AFFINITY; BLEEDING; COMPARATIVE STUDY; COMPETITIVE INHIBITION; DRUG MECHANISM; ENZYME ACTIVE SITE; ENZYME ACTIVITY; HYDROLYSIS; IN VITRO STUDY; NONHUMAN; PARTIAL THROMBOPLASTIN TIME; PRIORITY JOURNAL; PROTEIN DEGRADATION; ANTAGONISTS AND INHIBITORS; BINDING SITE; CHEMISTRY; DRUG DESIGN; HUMAN; KINETICS; SERUM;

ALLOSTERIC SITE; ANTICOAGULANTS; BINDING SITES; BIOMIMETIC MATERIALS; DRUG DESIGN; FACTOR XIA; GLUCOSIDES; HUMANS; KINETICS; PROTEIN BINDING; SERUM; SULFURIC ACID ESTERS;

EID: 84938557258     PISSN: 00493848     EISSN: 18792472     Source Type: Journal    
DOI: 10.1016/j.thromres.2015.04.017     Document Type: Article

References (58)

1. W. Ageno, A.S. Gallus, A. Wittkowsky, M. Crowther, E.M. Hylek, G. Palareti, and et al. Oral anticoagulants: Antithrombotic therapy and prevention of thrombosis, 9th ed.: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines Chest 141 2 Suppl. 2012 e44S e88S
2. D.A. Garcia, T.P. Baglin, J.I. Weitz, M.M. Samama, and American College of Chest Physicians Parenteral anticoagulants: Antithrombotic therapy and prevention of thrombosis, 9th ed.: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines Chest 141 2 Suppl. 2012 e24S e43S
3. M.A. Crowther, and T.E. Warkentin Bleeding risk and the management of bleeding complications in patients undergoing anticoagulant therapy: focus on new anticoagulant agents Blood 111 2008 4871 4879
4. W.F. Peacock, M.M. Gearhart, and R.M. Mills Emergency management of bleeding associated with old and new oral anticoagulants Clin Cardiol 35 2012 730 737
5. J. Hirsh, S.S. Anand, J.L. Halperin, and V. Fuster Guide to anticoagulant therapy: Heparin: a statement for healthcare professionals from the American Heart Association Circulation 103 2001 2994 3018
6. R.A. Al-Horani, P. Ponnusamy, A.Y. Mehta, D. Gailani, and U.R. Desai Sulfated pentagalloyl-glucoside is a potent, allosteric, and selective inhibitor of factor XIa J Med Chem 56 2013 867 878
7. R.A. Al-Horani, and U.R. Desai Designing allosteric inhibitors of factor XIa. Lessons from the interactions of sulfated pentagalloylglucopyranosides J Med Chem 57 2014 4805 4818
8. U. Seligsohn FXI deficiency in humans J Thromb Haemost 7 2009 84 87
9. K. Gomez, and P. Bolton-Maggs Factor XI deficiency Haemophilia 14 2008 1183 1189
10. S. Dusga, and O. Salomon Factor XI deficiency Semin Thromb Hemost 35 2009 416 425
11. J.C.M. Meijers, W.L.H. Tekelenburg, B.N. Bouma, R.M. Bertina, and F.R. Rosendaal High levels of coagulation factor XI as a risk factor for venous thrombosis N Engl J Med 342 2000 696 701
12. O. Salmon, D.M. Steinberg, N. Korean-Morag, D. Tanne, and U. Seligsohn Reduced incidence of ischemic stroke in patients with severe factor XI deficiency Blood 111 2008 4113 4117
13. J.I. Berliner, A.C. Rybicki, R.C. Kaplan, E.S. Monrad, R. Freeman, and H.H. Billett Elevated levels of factor XI are associated with cardiovascular disease in women Thromb Res 107 2002 55 60
14. E.C. Löwenberg, J.C.M. Meijers, B.P. Monia, and M. Levi Coagulation factor XI as a novel target for antithrombotic treatment J Thromb Haemost 8 2010 2349 2357
15. 3-induced injury of the carotid artery in the mouse Thromb Haemost 87 2002 774 776
16. W.A. Schumacher, J.M. Luettgen, M.L. Quan, and D.A. Seiffert Inhibition of factor XIa as a new approach to anticoagulation Arterioscler Thromb Vasc Biol 30 2010 388 392
17. P.M. Mannucci, K.A. Bauer, E. Santagostino, E. Faioni, S. Barzegar, R. Coppola, and et al. Activation of the coagulation cascade after infusion of a factor XI concentrate in congenitally deficient patients Blood 84 1994 1314 1319
18. H.R. Büller, C. Bethune, S. Bhanot, D. Gailani, B.P. Monia, G.E. Raskob, and et al. Factor XI antisense oligonucleotide for prevention of venous thrombosis N Engl J Med 372 2015 232 240
19. B.L. Henry, J.N. Thakkar, A. Liang, and U.R. Desai Sulfated, low molecular weight lignins inhibit a select group of heparin-binding serine proteases Biochem Biophys Res Commun 417 2012 382 386
20. Y.W. Wu, and Y.H. Tsai A rapid transglutaminase assay for high-throughput screening applications J Biomol Screen 11 2006 836 843
21. R. Karuturi, R.A. Al-Horani, S.C. Mehta, D. Gailani, and U.R. Desai Discovery of allosteric modulators of factor XIa by targeting hydrophobic domains adjacent to its heparin-binding site J Med Chem 56 2013 2415 2428
22. Y. Geng, I.M. Verhamme, S.A. Smith, Q. Cheng, M. Sun, J.P. Sheehan, and et al. Factor XI anion-binding sites are required for productive interactions with polyphosphate J Thromb Haemost 11 2013 2020 2028
23. A.S. Wolberg Plasma factor XIII: understanding the 99% Blood 123 2014 1623 1624
24. J.H. Levy, and C. Greenberg Biology of Factor XIII and clinical manifestations of Factor XIII deficiency Transfusion 53 2013 1120 1131
25. O. Sperandio, K.C. Wildhagen, R. Schrijver, S. Wielders, B.O. Villoutreix, and G.A. Nicolaes Identification of novel small molecule inhibitors of activated protein C Thromb Res 133 2014 1105 1114
26. E. Hooley, P.A. McEwan, and J. Emsley Molecular modeling of the prekallikrein structure provides insights into high-molecular-weight kininogen binding and zymogen activation J Thromb Haemost 5 2007 2461 2466
27. U.R. Desai, M. Petitou, I. Björk, and S.T. Olson Mechanism of heparin activation of antithrombin. Role of individual residues of the pentasaccharide activating sequence in the recognition of native and activated states of antithrombin J Biol Chem 273 1998 7478 7487
28. D.M. Tollefsen Heparin cofactor II Adv Exp Med Biol 425 1997 35 44
29. S.K. Hartman, and J. Teruya Practice guidelines for reversal of new and old anticoagulants Dis Mon 58 2012 448 461
30. G. Montalescot, W.M. Zapol, A. Carvalho, D.R. Robinson, A. Torres, and E. Lowenstein Neutralization of low molecular weight heparin by polybrene prevents thromboxane release and severe pulmonary hypertension in awake sheep Circulation 82 1990 1754 1764
31. B.J. Desai, R. Boothello, A.Y. Mehta, J.N. Scarsdale, H.T. Wright, and U.R. Desai Interaction of thrombin with sucrose octasulfate Biochemistry 50 2011 6973 6982
32. A. Teramoto, Y. Takagi, A. Hachimori, and K. Abe Interaction of albumin with polysaccharides containing ionic groups Polym Adv Technol 10 1999 681 686
33. D. Gailani, and S.B. Smith Structural and functional features of factor XI J Thromb Haemost 7 2009 75 78
34. J. Emsley, P.A. McEwan, and D. Gailani Structure and function of factor XI Blood 115 2010 2569 2577
35. D.H. Ho, K. Badellino, F.A. Baglia, and P.N. Walsh A binding site for heparin in the apple 3 domain of factor XI J Biol Chem 273 1998 16382 16390
36. M. Zhao, T. Abdel-Razek, M.F. Sun, and D. Gailani Characterization of a heparin-binding site on the heavy chain of factor XI J Biol Chem 273 1998 31153 31159
37. B.N. Bouma, and J.H. Griffin Human blood coagulation factor XI: purification, properties, and mechanism of activation by activated factor XII J Biol Chem 252 1997 6432 6437
38. S.H. Choi, S.A. Smith, and J.H. Morrissey Polyphosphate is a cofactor for the activation of factor XI by thrombin Blood 118 2011 6963 6970
39. D.V. Kravtsov, A. Matafonov, E.I. Tucker, M.F. Sun, P.N. Walsh, A. Gruber, and et al. Factor XI contributes to thrombin generation in the absence of factor XII Blood 114 2009 452 458
40. J.A. Oliver, D.M. Monroe, H.R. Roberts, and M. Hoffman Thrombin activates factor XI on activated platelets in the absence of factor XII Arterioscler Thromb Vasc Biol 19 1999 170 177
41. K. Naito, and K. Fujikawa Activation of human blood coagulation factor XI independent of factor XII: factor XI is activated by thrombin and factor XIa in the presence of negatively charged surfaces J Biol Chem 266 1991 7353 7358
42. J.H. Morrissey, S.H. Choi, and S.A. Smith Polyphosphate: an ancient molecule that links platelets, coagulation, and inflammation Blood 119 2012 5972 5979
43. S.A. Smith, S.H. Choi, R. Davis-Harrison, J. Huyck, J. Boettcher, C.M. Rienstra, and et al. Polyphosphate exerts differential effects on blood clotting, depending on polymer size Blood 116 2010 4353 4359
44. Y. Geng, I. Verhamme, S.B. Smith, M.F. Sun, A. Matafonov, Q. Cheng, and et al. The dimeric structure of factor XI and zymogen activation Blood 121 2013 3962 3969
45. F.A. Baglia, D. Gailani, J.A. López, and P.N. Walsh Identification of a binding site for glycoprotein Ibalpha in the Apple 3 domain of factor XI J Biol Chem 279 2004 45470 45476
46. F.A. Baglia, C.N. Shrimpton, J. Emsley, K. Kitagawa, Z.M. Ruggeri, J.A. López, and et al. Factor XI interacts with the leucine-rich repeats of glycoprotein Ibalpha on the activated platelet J Biol Chem 279 2004 49323 49329
47. F.A. Baglia, K.O. Badellino, C.Q. Li, J.A. Lopez, and P.N. Walsh Factor XI binding to the platelet glycoprotein Ib-IX-V complex promotes factor XI activation by thrombin J Biol Chem 277 2002 1662 1668
48. D.H. Ho, F.A. Baglia, and P.N. Walsh Factor XI binding to activated platelets is mediated by residues R(250), K(255), F(260), and Q(263) within the apple 3 domain Biochemistry 39 2000 316 323
49. T.N. Miller, D. Sinha, T.R. Baird, and P.N. Walsh A catalytic domain exosite (Cys527-Cys542) in factor XIa mediates binding to a site on activated platelets Biochemistry 46 2007 14450 14460
50. S.H. Choi, J.N. Collins, S.A. Smith, R.L. Davis-Harrison, C.M. Rienstra, and J.H. Morrissey Phosphoramidate end labeling of inorganic polyphosphates: facile manipulation of polyphosphate for investigating and modulating its biological activities Biochemistry 49 2010 9935 9941
51. S. Krishnaswamy Exosite-driven substrate specificity and function in coagulation J Thromb Haemost 3 2005 54 67
52. M. Merdanovic, T. Mönig, M. Ehrmann, and M. Kaiser Diversity of allosteric regulation in proteases ACS Chem Biol 8 2013 19 26
53. R. Nussinov, and C.J. Tsai Allostery in disease and in drug discovery Cell 153 2013 293 305
54. P. Hauske, C. Ottmann, M. Meltzer, M. Ehrmann, and M. Kaiser Allosteric regulation of proteases Chembiochem 9 2008 2920 2928
55. G.T. Gunnarsson, and U.R. Desai Interaction of sulfated flavanoids with antithrombin: lessons on the design of organic activators J Med Chem 45 2002 4460 4470
56. B.L. Henry, J. Connell, A. Liang, C. Krishnasamy, and U.R. Desai Interaction of antithrombin with sulfated, low molecular weight lignins. Opportunities for potent, selective modulation of antithrombin function J Biol Chem 284 2009 20897 20908
57. E.A. Nutescu, W.E. Dager, J.S. Kalus, J.J. Lewin III, and M.D. Cipolle Management of bleeding and reversal strategies for oral anticoagulants: clinical practice considerations Am J Health Syst Pharm 70 2013 1914 1929
58. S. Yates, and R. Sarode Novel thrombin and factor Xa inhibitors: challenges to reversal of their anticoagulation effects Curr Opin Hematol 20 2013 552 557